Form D · Biotechnology
Lazzaro Medical, Inc.
Boulder, CO · CIK 0002014886
Offering snapshot reported Jul 22, 2024 · SEC filing
- Reported sold
- $4.92M Offering amount: $7.52M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 9, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2024 | Initial | $4,920,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519356
Simple Agreement for Future Equity; Convertible Promissory Notes
Source: Form D, filed Jul 22, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| D. Dawn Bitz | Executive |
| Robert A. Israel | Director, Executive, Promoter |
| Richard S. Lazzaro, M.D. | Director, Executive, Promoter |
| Frederick J. Onorato | Executive |
| James R. Polsen | Executive |
| Ryan G. Redford | Executive |
| Robert J. Wiesenberg | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1215 Spruce Street
Boulder, CO, 80302
Boulder, CO, 80302